For FLT3-mutant subtypes of AML, triple therapy based on venetoclax, decitabine, and an FLT3 inhibitor also revealed satisfactory response rates in both ND-AML and R/R AML [61]. This evidence concerns the gene FLT3 and acute myeloid leukemia.